Our pipeline is focused on disease-modifying treatments of Alzheimer’s disease (AD), Progressive Supranuclear Palsy (PSP) and mild blast-induced traumatic brain injury (mb-TBI)  which can result in long-term neurodegenerative processes.

Tau Biologic’s most advanced candidate in development is a humanized monoclonal antibody against an extremely noxious protein which has versatility as a therapeutic target in presently untreatable neurodegenerative diseases.

Second generation candidates [TBL-110 Series], are being designed with improved brain penetration.